Anavex Life Sciences Corp Stock Research

Market Summary

USD9.18-0.14

Market Closed

-1.50%

AVXL Stock Price

AVXL RSI Chart

AVXL Valuation

Market Cap

736.6M

Price/Earnings (Trailing)

-13.97

Price/Sales (Trailing)

291.16

EV/EBITDA

-11.62

Price/Free Cashflow

-29.02

AVXL Price/Sales (Trailing)

AVXL Profitability

Return on Equity

-37.05%

Return on Assets

-33.74%

Free Cashflow Yield

-3.45%

AVXL Fundamentals

AVXL Revenue

Revenue Y/Y

-96.92%

Revenue Q/Q

-94.02%

AVXL Earnings

Earnings (TTM)

-52.7M

Earnings Y/Y

-25.57%

Earnings Q/Q

-1.05%

Price Action

52 Week Range

7.3615.24

(Low)(High)

Last 7 days

-0.9%

Last 30 days

12.8%

Last 90 days

-5.2%

Trailing 12 Months

-5.5%

AVXL Financial Health

AVXL Investor Care

Shares Dilution (1Y)

3.98%

Peers (Alternatives to Anavex Life Sciences)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
GILD	95.3B	27.0B	-7.15%	22.78%	17.06	3.52	-1.56%	23.65%
MRNA	49.5B	15.1B	-3.01%	-12.71%	10.35	3.29	-33.37%	-67.32%
EXAS	14.6B	2.1B	26.64%	50.73%	-28.24	7	17.95%	30.68%
INCY	13.8B	3.4B	-16.85%	-19.85%	42.55	4.07	13.67%	-65.23%
MID-CAP
EXEL	6.2B	1.7B	3.88%	3.32%	40.19	3.71	9.41%	-48.42%
SYNH	4.3B	5.4B	5.83%	-44.73%	28.86	0.79	1.37%	-38.84%
DNLI	4.0B	-	17.83%	16.01%	-10.8	36.9	122.90%	-29.67%
ARWR	3.5B	272.8M	-7.43%	-4.15%	-23.32	12.84	3.56%	-34.35%
SMALL-CAP
AVXL	736.6M	-	12.78%	-5.46%	-13.97	291.16	-	-22.02%
NVAX	641.1M	-	-3.13%	-86.56%	-0.55	0.32	72.89%	12.32%
PGEN	314.2M	23.2M	1.65%	-10.87%	12.65	13.52	-45.75%	126.39%
SRNE	170.9M	-	-71.28%	-88.95%	-0.25	2.64	22.40%	-42.61%
NNVC	12.6M	-	-18.80%	-49.77%	-1.85	-	-	19.06%
TENX	7.0M	-	-0.93%	-97.50%	-0.39	-	-	71.01%

Financials for Anavex Life Sciences

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q1	2021Q4	2021Q3
Revenue	NaN%					54,100
Operating Expenses	5.6%	-44,655,838	-47,325,250	-37,108,809	-	-
S&GA Expenses	-0.2%	13,287,563	13,320,153	11,295,219	-	-
R&D Expenses	6.5%	44,028,229	41,326,227	35,598,342	-	-
EBITDA	-10.7%	-47,549,108	-42,946,357	-	-	-
EBITDA Margin	-9.0%	-10.84	-9.95	-	-	-
Earnings Before Taxes	-5.3%	-52,408,072	-49,758,804	-42,977,449	-	-
EBT Margin	-8.9%	-10.84	-9.95	-	-	-
Interest Expenses	7007.0%	2,209,696	31,092	32,730	-	-
Net Income	-5.3%	-52,736,738	-50,067,270	-43,218,525	-	-
Net Income Margin	-8.9%	-10.91	-10.01	-	-	-
Free Cahsflow	6.4%	-26,531,166	-28,335,890	-	-	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	7.3%	159	148	153	160	160
Cash Equivalents	6.9%	153	144	149	153	153
Liabilities	5.8%	14.00	13.00	10.00	-	-
Current Liabilities	17.5%	9.00	8.00	-	-	-
Shareholder's Equity	7.4%	145	135	142	151	152
Retained Earnings	-5.1%	-271	-258	-245	-231	-218
Additional Paid-In Capital	5.9%	417	394	388	382	371
Shares Outstanding	2.8%	80.00	78.00	78.00	78.00	77.00

Cashflow (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	4.3%	-25,380,261	-26,531,166	-24,237,864	-27,868,437	-28,335,890
Share Based Compensation	-2.4%	19,347,584	19,816,976	18,379,242	15,488,849	13,794,160
Cashflow From Financing	34.2%	25,504,667	19,006,659	21,287,980	23,507,744	105,819,107

Risks for AVXL

What is the probability of a big loss on AVXL?

100%

Probability that Anavex Life Sciences stock will be more than 20% underwater in next one year

88.1%

Probability that Anavex Life Sciences stock will be more than 30% underwater in next one year.

75.8%

Probability that Anavex Life Sciences stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does AVXL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Anavex Life Sciences was unfortunately bought at previous high price.

Drawdowns

Returns for AVXL

Cumulative Returns on AVXL

30.5%

10-Year Cumulative Returns

10.9%

7-Year Cumulative Returns

27.3%

5-Year Cumulative Returns

30.7%

3-Year Cumulative Returns

What are the long-term rolling returns for AVXL?

FIve years rolling returns for Anavex Life Sciences.

Annualized Returns

Which funds bought or sold AVXL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-26	ProShare Advisors LLC	reduced	-11.7	-25,980	116,115	-%
2023-05-22	AMERIPRISE FINANCIAL INC	reduced	-0.52	-25,110	286,890	-%
2023-05-18	JPMORGAN CHASE & CO	added	31.26	88,000	495,000	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-18.84	-111,000	337,000	-%
2023-05-17	Advisory Services Network, LLC	reduced	-2.02	-4,272	41,565	-%
2023-05-16	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	62.39	1,745,900	5,217,360	-%
2023-05-16	JANE STREET GROUP, LLC	added	52.97	53,001	180,493	-%
2023-05-16	Rockefeller Capital Management L.P.	sold off	-100	-25,000	-	-%
2023-05-15	Saturna Capital CORP	added	45.93	39,934	153,832	-%
2023-05-15	LIBERTY ONE INVESTMENT MANAGEMENT, LLC	reduced	-3.35	-13,067	110,767	0.01%

Latest Funds Activity

Are funds buying AVXL calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own AVXL

No. of Funds

Anavex Life Sciences News

Schedule 13G FIlings of Anavex Life Sciences

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	5.32%	4,144,500	SC 13G/A
Feb 09, 2023	state street corp	7.46%	5,812,605	SC 13G/A
Jan 31, 2023	blackrock inc.	7.2%	5,578,159	SC 13G/A
Feb 09, 2022	state street corp	5.04%	3,834,034	SC 13G
Feb 09, 2022	vanguard group inc	5.05%	3,841,570	SC 13G
Feb 03, 2022	blackrock inc.	6.9%	5,262,666	SC 13G/A
Feb 16, 2021	park west asset management llc	0.0%	0	SC 13G/A
Feb 02, 2021	blackrock inc.	5.5%	3,678,763	SC 13G
Mar 09, 2020	blackrock inc.	4.96%	2,910,221	SC 13G/A
Feb 14, 2020	park west asset management llc	6.0%	3,370,000	SC 13G/A

AVXL Fair Value

Show Fair-Value

Recent SEC filings of Anavex Life Sciences

View All Filings

Date Filed	Form Type	Document
May 24, 2023	8-K	Current Report
May 09, 2023	10-Q	Quarterly Report
Apr 14, 2023	8-K	Current Report
Apr 04, 2023	DEFA14A	DEFA14A
Apr 04, 2023	DEF 14A	DEF 14A
Apr 04, 2023	4	Insider Trading
Apr 04, 2023	4	Insider Trading
Apr 04, 2023	4	Insider Trading
Apr 04, 2023	4	Insider Trading
Apr 04, 2023	4	Insider Trading

Latest Insider Trading transactions for AVXL

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-05-25	Skarpelos Athanasios	sold	-453,000	9.06	-50,000	-
2022-05-25	Skarpelos Athanasios	acquired	46,000	0.92	50,000	-
2021-06-29	MISSLING CHRISTOPHER U	sold	-1,342,120	26.00	-51,620	president and ceo
2021-06-29	MISSLING CHRISTOPHER U	acquired	68,138	1.32	51,620	president and ceo
2021-06-29	Boenisch Sandra	acquired	699,163	4.19424	166,696	pfo and treasurer
2021-06-29	Boenisch Sandra	sold	-4,422,440	26.53	-166,696	pfo and treasurer
2021-05-21	FAVUS ELLIOT	acquired	280,820	1.93669	145,000	-
2021-05-21	FAVUS ELLIOT	sold	-1,696,280	11.6985	-145,000	-
2021-05-17	Donhauser Peter D.O.	bought	10,930	10.93	1,000	-
2021-02-24	FAVUS ELLIOT	acquired	445,390	3.0611	145,500	-

About Anavex Life Sciences

Christopher U. Missling

www.anavex.com

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

AVXL Income Statement

2023-03-31

Condensed Interim Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Operating expenses
General and administrative	$ 2,882,568	$ 2,915,158	$ 6,199,604	$ 5,982,109
Research and development	11,306,591	8,604,589	23,373,510	17,261,028
Total operating expenses	14,189,159	11,519,747	29,573,114	23,243,137
Operating loss	(14,189,159)	(11,519,747)	(29,573,114)	(23,243,137)
Other income (expenses)
Grant income			25,000
Research and development incentive income	749,681	835,513	1,483,271	1,646,243
Interest income, net	1,465,221	7,578	2,732,839	12,488
Other financing expense	(964,344)		(964,344)
Foreign exchange (loss) gain	(118,678)	268,645	247,305	324,008
Total other income, net	1,131,880	1,111,736	3,524,071	1,982,739
Net loss before provision for income taxes	(13,057,279)	(10,408,011)	(26,049,043)	(21,260,398)
Income tax expense, current	(50,000)	(29,800)	(29,954)	(59,780)
Net loss and comprehensive loss	$ (13,107,279)	$ (10,437,811)	$ (26,078,997)	$ (21,320,178)
Net Loss per share
Basic and diluted	$ (0.17)	$ (0.14)	$ (0.33)	$ (0.28)
Weighted average number of shares outstanding
Basic and diluted	$ 78,304,363	$ 76,248,603	$ 78,138,940	$ 76,121,792

AVXL Balance Sheet

2023-03-31

Condensed Interim Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2023	Sep. 30, 2022
Current
Cash and cash equivalents	$ 153,466,962	$ 149,157,861
Incentive and tax receivables	4,737,661	3,192,580
Prepaid expenses and other current assets	981,774	354,162
Total Assets	159,186,397	152,704,603
Current Liabilities
Accounts payable	6,281,742	3,824,777
Accrued liabilities - Note 4	6,822,838	5,944,953
Deferred grant income - Note 3	916,763	443,831
Total Liabilities	14,021,343	10,213,561
Commitments and Contingencies - Note 6
Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share
Capital stock Authorized:200,000,000 common stock, par value $0.001 per share 80,235,398 common shares (September 30, 2022 - 77,942,815)	80,236	77,944
Additional paid-in capital	416,727,598	387,976,881
Accumulated deficit	(271,642,780)	(245,563,783)
Total Stockholders' Equity	145,165,054	142,491,042
Total Liabilities and Stockholders' Equity	$ 159,186,397	$ 152,704,603